Lung Cancer

17 protocols meet the specified criteria.

• 20240178

  A Phase 3, Open Label, Multicenter, Randomized Study of First Line Tarlatamab in combination with Durvalumab, Carboplatin and Etoposide versus Durvalumab, Carboplatin and Etoposide in Untreated Extensive Stage Small-Cell Lung Cancer (DeLLphi-312)

• A081801

  Integration of Immunotherapy into Adjuvant Therapy for Resected NSCLC: ALCHEMIST CHEMO-IO

• A151804

  Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events

• A211901

  Reaching Rural Cancer Survivors Who Smoke Using Test-Based Cessation Interventions

• D702GC00001

  A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab Monotherapy for the First-line Treatment of Patients with PD-L1-high Metastatic Non-small Cell Lung Cancer (ARTEMIDE-Lung04)

• D763QC00001

  A Phase III, Randomised, Open-Label, Multicentre Study of Datopotamab Deruxtecan or Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung17)

• EAY191

  Molecular Analysis for Combination Therapy Choice (ComboMATCH)

• EAY191-N5

  A Randomized Trial of Neratinib, A Pan-ErbB Inhibitor, Alone or in Combination with Palbociclib, A CDK4/6 Inhibitor, in Patients with HER2+ Gynecologic Cancers and Other Solid Tumors - A ComboMATCH Treatment Trial

• GRAIL-MA-002

  REACH Study: Real-world Evidence to Advance Multi-Cancer Early Detection Health Equity (REACH/Galleri-Medicare study)

• LUNGMAP

  A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)

• M23-384

  A Phase 3 Randomized, Open Label, Multicenter Study to Evaluate the Safety and Efficacy of ABBV-706 versus Standard of Care in Subjects with Relapsed/Refractory Small Cell Lung Cancer (SCLC)

• NRG-CC014

  Radiation Therapy for High-Risk Asymptomatic Bone Metastases: A Pragmatic Multicenter Randomized Phase 3 Clinical Trial (PREEMPT)

• NRG-LU007

  Randomized Phase II/III Trial of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial

• NRG-LU008

  Phase III Prospective Randomized Trial of Primary Lung Tumor Stereotactic Body Radiation Therapy Followed by Concurrent Mediastinal Chemoradiation for Locally Advanced Non-Small Cell Lung Cancer

• S1800E

  LUNGMAP: A Randomized Phase II/III Study of Docetaxel and Ramucirumab with or without Cemiplimab (REGN2810) for Participants Previously Treated with Platinum-based Chemotherapy and Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (LungMAP Non-Matched Sub-Study)

• S1900J

  A Phase II Study of Amivantamab SC (subcutaneous) in Participants with MET Amplification-Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNGMAP Sub-Study)

• S1900K

  A Randomized Phase II Study of Tepotinib with or without Ramucirumab in Participants with MET Exon 14 Skipping Positive Stage IV or Recurrent Non-small Cell Lung Cancer (Lung-Map Sub-Study)